0001816518-21-000001.txt : 20210203 0001816518-21-000001.hdr.sgml : 20210203 20210203172341 ACCESSION NUMBER: 0001816518-21-000001 CONFORMED SUBMISSION TYPE: D/A PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20210203 DATE AS OF CHANGE: 20210203 EFFECTIVENESS DATE: 20210203 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Nine Square Therapeutics Corp CENTRAL INDEX KEY: 0001816518 IRS NUMBER: 850634503 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D/A SEC ACT: 1933 Act SEC FILE NUMBER: 021-370079 FILM NUMBER: 21587383 BUSINESS ADDRESS: STREET 1: 230 PARK AVENUE, SUITE 2800 CITY: NEW YORK STATE: NY ZIP: 10169 BUSINESS PHONE: 781-367-5419 MAIL ADDRESS: STREET 1: 230 PARK AVENUE, SUITE 2800 CITY: NEW YORK STATE: NY ZIP: 10169 FORMER COMPANY: FORMER CONFORMED NAME: Nine Square Therapeutics, Inc. DATE OF NAME CHANGE: 20200630 D/A 1 primary_doc.xml X0708 D/A LIVE 0001816518 Nine Square Therapeutics Corp 230 PARK AVENUE, SUITE 2800 NEW YORK NY NEW YORK 10169 781-367-5419 DELAWARE Waltz Therapeutics, Inc. Nine Square Therapeutics, Inc. Corporation true 2020 Spiros Liras c/o Nine Square Therapeutics Corp 230 Park Avenue, Suite 2800 New York NY NEW YORK 10169 Executive Officer Director Seth Harrison c/o Nine Square Therapeutics Corp 230 Park Avenue, Suite 2800 New York NY NEW YORK 10169 Director Michael Ehlers c/o Nine Square Therapeutics Corp . 230 Park Avenue, Suite 2800 New York NY NEW YORK 10169 Director Matthew Jacobson c/o Nine Square Therapeutics Corp 230 Park Avenue, Suite 2800 New York NY NEW YORK 10169 Director Biotechnology Decline to Disclose 06b true 0001816518-20-000001 2020-06-16 false true false 0 50000000 4200000 45800000 false 1 0 0 0 false Nine Square Therapeutics Corp /s/ Spiros Liras Spiros Liras Chief Executive Officer 2021-02-03